top of page
surf break copy_edited.jpg
surbreak-19.png
Search

xCures announces real-world biomarker study for patients with FGFR-mutant bladder cancer

Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The study is supported by Tyra Biosciences, Inc., a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. This study will investigate a patient’s tumor DNA through their blood and urine samples to provide information on their treatment and what options might be available if their disease worsens.


Recent Posts

See All

Comments


WM360_logo-18.png
bottom of page